Bharat Biotech on Wednesday said its booster dose of Covaxin has generated neutralising antibody responses against both Omicron and Delta variants of COVID-19.
"A study conducted at Emory University demonstrated that subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series have witnessed neutralising of the SARS-CoV-2 Omicron and Delta variants," the vaccine major said in a statement.
Citing the study results, Bharat Biotech noted that more than 90 percent of all individuals boosted with Covaxin showed neutralising antibodies.
"As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern. Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants," it added.
"These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations," Emory Vaccine Center Assistant Professor Mehul Suthar, who led the laboratory analysis, noted.
Last week, Bharat Biotech had said that no paracetamol or painkiller is recommended after being vaccinated with Covaxin, The company noted that Covaxin is formulated uniquely such that the same dosage can be administered to adults and children alike.
(With inputs from PTI)
(Edited by : Aditi Gautam)
First Published: IST